Kornimate/medical-research-clean huggingface dataset:
retinal vessel diameter in branch retinal vein occlusion

Conditions: Branch Retinal Vein Occlusion

Summary: the authors investigated the consecutive change of retinal vessel's diameter in affected eye and fellow eye of branch retinal vein occlusion.

twenty five consecutive patients who had undergone intravitreal bevacizumab injection for branch retinal vein occlusion with macular edema were included in this study. all subjects were enrolled between april, 2012 and april, 2013 in the department of ophthalmology, kyungpook national university hospital.

Eligibility criteria:
inclusion criteria: * best-corrected visual acuity less than 20/40 * central subfield macular thickness (csmt) 300 μm or greater on spectral-domain optical coherence tomography exclusion criteria: * patients with recurrent brvo * history of previous treatments for brvo including vitreoretinal surgery, intravitreal injection, subtenon injection or laser photocoagulation * patients with diabetes or dyslipidemia * iop ≥ 22mmhg, treatment for glaucoma, a family history of glaucoma, or optic neuropathy * high myopia (\ 6 diopters) or a history of refractive surgeries * co-existing retinal disease other than brvo * corneal diseases include ulcer, keratoconus and a history of corneal laceration * cataract and other media opacities resulting in visual impairment or poor fundus images
il-1ra, acute exercise, and beta-cell function

Conditions: Type 2 Diabetes Mellitus

Summary: subjects (n=48) with poorly-controlled type 2 diabetes (hba1c\>7%) will be assigned to one of the 4 following interventions in a randomised, parallel group design: \[i\] control (placebo injection; no exercise), \[ii\] anakinra (100 mg subcutaneous injection of human recombinant interleukin-1 receptor antagonist), \[iii\] exercise (1 h cycle ergometry at 75% vo2max), \[iv\] anakinra + exercise. pancreatic beta-cell function (plasma insulin responses) will be measured before and after each intervention using a hyperglycemic clamp (5.4 mm above basal glucose) combined with glp-1 infusion (0.5 pmol/kg/min) and arginine injection (5 g bolus).


Eligibility criteria:
inclusion criteria: * type 2 diabetes with hba1c \>7% exclusion criteria: * hba1c \>7% * age \ 80 y * bmi \ 40 kg/m2 * pregnancy * evidence of chronic haematological/renal/hepatic/pulmonary/heart disease * \>2kg weight change in prior 6 months * alcohol consumption (men: \>14 drinks/week; women: \>7 drinks/week) * smoking * physical activity of \>150 min/week * contraindication to exercise * contraindication to use of anakinra

Keywords: exercise il-1ra beta-cell function type 2 diabetes
feasibility and psychometric properties of paper vs. web vs. automated telephone administration of patient reported outcome surveys

Conditions: Colon Cancer; Rectal Cancer

Summary: it can be difficult to obtain the perspective of patients who have had bowel surgery. this study is being done because the investigators are trying to find out whether patient-reported outcomes, (results reported to investigators by the patient), on a regular basis, will help the investigators provide better patient care and symptom management. therefore, the purpose of this study is to determine if it is possible and if it is useful to their medical care for patients who have had bowel surgery to complete surveys about their symptoms on a regular basis. in this study the surveys are completed from home, by web or by telephone, every month for 6 months. the results of this study will guide the design of large research studies on cancer-related bowel function. the purpose of this study is to develop a bowel function questionnaire for patients with colorectal cancer. the questionnaire will be used in future clinical trials to assess bowel function.


Eligibility criteria:
inclusion criteria: aim 1: * stage i-iii rectal cancer * post sphincter preserving surgery with restoration of bowel continuity within last 4-6 weeks at mskcc. * access to web and email from home * web avidity (≥2 uses of email/week) * able to read and write in english * age ≥ 18 aim 2: * stage i-iii colon and rectal cancer * post surgical resection of primary tumor at mskcc * access to web and email from home * web avidity (≥2 uses of email/week) * able to read and write in english * age ≥ 18 exclusion criteria: aim 1: * metastatic disease - auditory, visual or motor impairment that would preclude ability to use telephone and/or computer. * stoma * participated in aim 2 * definitive sps = transanal excision (tae) or transanal endoscopic microsurgery (tem) aim 2: * metastatic disease - auditory, visual or motor impairment that would preclude ability to use telephone and/or computer. * stoma * participated in aim 1

Keywords: quality of life patient outcomes questionaires 11-101
blended learning versus face-to-face learning in cardiac physiotherapy students

Conditions: Learning; Students

Summary: blended learning (bl) combines both face-to-face learning (fl) and online learning. there is no evidence about the effects of a bl program in cardiac physiotherapy education. this study aimed at comparing the effectiveness of a bl program versus a fl program in physiotherapy degree students on knowledge, competencies, satisfaction, perceptions, usability, bl acceptance, attitudes and behaviours. an assessor-blinded randomized trial was performed.

blended learning (bl) combines both face-to-face learning (fl) and online learning. there is no evidence about the effects of a bl program in cardiac physiotherapy education. this study aimed at comparing the effectiveness of a bl program versus a fl program in physiotherapy degree students on knowledge, competencies, satisfaction, perceptions, usability, bl acceptance, attitudes and behaviours. an assessor-blinded randomized trial was performed. a total of 100 students were randomly allocated to a bl group (blg, n=48), or a fl group (flg, n=52). the blg received face-to-face classes plus online re-sources (online syllabus, moodle, scientific-based videos and websites, activities, glossary, and apps). the flg received face-to-face classes and hardcopy resources (hardcopy syl-labus, scientific-based information, activities, and glossary). knowledge, ethical and gen-der competencies, satisfaction, and perceptions were assessed pre- and post-intervention. usability, bl acceptance, attitudes and behaviours were assessed post-intervention.

Eligibility criteria:
inclusion criteria: * being a student of degree in physiotherapy at the university of valencia. * willing to participate exclusion criteria: * previous cardiac physiotherapy training.
testing the feasibility and acceptability of social media and digital therapeutics to decrease vaping behaviors

Conditions: Nicotine Vaping; Nicotine Use Disorder

Summary: use of vaping products (e.g., electronic nicotine delivery systems, e-cigarettes) has been increasing rapidly, particularly among teens and young adults. with limited information on the long-term effects of vaping products, health information about vaping has been somewhat unclear in regards to associated health risks. teens and young adults may be reluctant to disclose their use of vaping products to parents or health providers and instead turn to social media to share and seek out information regarding vaping risks and cessation supports. thus, our current proposal outlines the use of social media to identify teens and young adults socially networking about vaping, the use of an online chatbot screen to evaluate individual cessation support needs, and the use of a digital intervention system to support vaping cessation. the mobile intervention used in this study is based on a widely-used evidence-based mobile intervention for combustible smoking (i.e., quitstart) and has been adapted for vaping and young adults to include an in-app chatbot to guide users to tailored content and to motivate and encourage their cessation efforts. we aim to integrate our social media recruitment and online screening approach to connect individuals with this mobile app intervention, and will conduct a randomized controlled trial to evaluate user engagement with and preliminary efficacy of the digital intervention on reducing vaping behaviors among teens and young adults.


Eligibility criteria:
inclusion criteria: * us resident * english speaking * have daily access to a smartphone * current vaping product user (p30d) * identified as socially networking about a desire to quit vaping and/or experiencing negative health outcomes due to vaping * vaping product user only (i.e., not using vaping as a means to support combustible smoking cessation)

Keywords: vaping mobile app intervention youth young adults chatbot nicotine social media
daily: vitamin d, aspirin, exercise, low saturated fat foods study in colorectal cancer patients with minimal residual disease

Conditions: Colorectal Cancer; Colon Cancer

Summary: to learn if lifestyle changes (such as diet and exercise) combined with daily aspirin and vitamin d can affect the likelihood of advanced colorectal cancer coming back (recurring)

primary objective: to estimate the ctdna clearance rate of colorectal cancer participants with minimal residual disease after 3 months of optimal lifestyle interventions secondary objectives: * to evaluate the dynamics of ctdna allele fractions after 3 months of optimal lifestyle interventions and every 3 months thereafter up to 12 months * to estimate the recurrence rate at 1 year in subjects who complete 3 months of optimal lifestyle interventions

Eligibility criteria:
inclusion criteria: * age ≥ 18 years at the time of study entry * ecog 0-1 * histologically documented high-risk stage ii, stage iii, or stage iv colorectal adenocarcinoma with no evidence of disease following definitive local therapy (including surgical resection or ablation) * no radiographic evidence of disease by contrast enhanced ct chest/abdomen/pelvis * presence of detectable ctdna mutation that matches mutations found in tumor tissue * completion of all standard of care adjuvant therapy * platelet count \>50,000 * ability to give informed consent * ability to complete all questionnaires involved in study exclusion criteria: * concurrent malignancy under active treatment * known active gastrointestinal bleeding or peptic ulcer disease * known hypersensitivity to vitamin d or aspirin * crcl\<30 ml/min within 30 days of starting the intervention * current usage of therapeutic anticoagulation (warfarin, eliquis, xarelto) * inability to safely participate in physical activity in the opinion of the treating oncologist * pregnant or nursing women. n.b.: urine pregnancy test will be administered as part of the screening process. * persistent hypercalcemia or conditions predisposing to hypercalcemia (i.e., hyperparathyroidism) * known symptomatic genitourinary stones
the women's health initiative memory study (the whims study)

Conditions: Dementia Syndromes

Summary: excessive memory decline or dementia affects an increasing number of women as they become older. the frequency of dementia doubles every 5 years beginning at age 60, making the discovery of ways to prevent or slow the disease imperative. previous studies have indicated that changes in memory may be associated with the female hormonal decline that occurs after menopause, but more research is needed to establish the link between menopause and poorer memory function. it is believed that taking the female hormones estrogen and/or progesterone may help improve women's health by protecting against memory decline. this study will evaluate the effects of female hormone replacement therapy (hrt) on the development and progression of memory loss in older women enrolled in the women's health initiative (whi) study.

diseases of the memory, including dementia and alzheimer's disease, are a primary health concern of the aging population. in just the last 30 years, the number of americans diagnosed with memory diseases has doubled. the beginning signs and symptoms of alzheimer's and dementia include mild forgetfulness, confusion, and disorientation with time and place. as the diseases advance, people often experience difficulty in carrying out normal activities, recognizing family and friends, and eventually speaking and comprehending. early identification and treatment for dementia and alzheimer's may help prevent and slow the progression of symptoms, but the most beneficial means of treatment is still unknown. previous studies have suggested a link between menopause and reduced memory function in women, possibly attributed to the dramatic decline in the levels of the female hormones estrogen and progesterone. hrt in postmenopausal women may help to curb memory loss and reduce risk of developing memory-related diseases. this study will evaluate the effects of female hrt on the development and progression of memory loss in older women enrolled in the whi study. participants in this study will be drawn from the whi study and will have previously been assigned to hrt with estrogen, hrt with estrogen plus progesterone, or placebo. during this study, participants will continue to take their assigned treatments from the whi study. participation will last up to 6 years. all participants will undergo baseline memory and thinking tests, including a mood assessment and tasks measuring memory and other brain functions. study staff will conduct a telephone interview with a close family member or friend. some participants may additionally undergo a 45-minute interview with a clinician, a blood draw, and a computerized tomography (ct) scan. all participants will repeat the baseline memory and thinking tests once annually for 6 years, and some participants will repeat the interview, blood draw, and ct scan at these annual visits as well.

Eligibility criteria:
inclusion criteria: * enrolled in the women's health initiative - hormone therapy trial * aged 65 - 79 years of age at time of enrollment

Keywords: cognition memory hormone therapy
cardiovascular effects of sunitinib therapy (crest)

Conditions: Renal Cell Carcinoma 4

Summary: tyrosine kinase inhibitors such as sunitinib are used in the treatment of renal cell carcinoma and have significant off-target effects with cardiac toxicity and resultant ventricular cardiac dysfunction being a major concern. however, the mechanisms of these effects in humans remains poorly defined, as are the clinical methods to risk stratify and identify patients who will ultimately suffer from cardiac dysfunction. the goal of this multi-center study is to characterize the cardiovascular measures of cardiac function; 2) comprehensive measures of arterial function and left ventricular afterload; 3) biomarkers reflective of the pathophysiologic alterations. through this work, the investigators will translate our basic understanding of sunitinib cardiotoxicity to humans and identify early predictors of sunitinib cardiotoxicity.

tyrosine kinase inhibitors such as sunitinib have dramatically improved the overall management of certaincancers including renal cell carcinoma. however, recent data suggest that these therapieshave significant off-target effects with cardiac toxicity, including significant hypertension and ventricular cardiac dysfunction being a major concern. however, the biologic mechanisms underlying cardiotoxicty in humans remain poorly defined. moreover, there is a critical need to develop methods to improve the risk stratification and early identification of patients who will suffer from hypertension and cardiac dysfunction with exposure to therapy. the over all objectives ofthis study are to further characterize the cardiovascular changes that occur with sunitinib exposure in order to improve our understanding of sunitib toxicity and determine early, mechanistically and clinically relevant predictors to identify patients at increased risk of hyptertension and cardiac dysfunction. the specific aims of this study are: 1) to define the changes in arterial hemodynamics that may occur with exposure to sunitinib, 2) to define the changes in sensitive echocardiographic measures of cardiac function that may occur with exposure to sunitinib, 3) to determine blood markers that are associated with changes in vasculature or cardiac function with exposure to sunitinib. and 4) to determine if there are early imaging or biomarker predictors of subitinib cardiotoxicity.

Eligibility criteria:
inclusion criteria: * patients with renal cell carcinoma newly undergoing therapy with sunitinib. * age greater than or equal to 18 years * ecog performance status 0,1,2 exclusion criteria: * any contraindication to sunitinib therapy of note, patients with prior cardiovascular history are not excluded from this study, as long as there are no contraindications to sunitinib therapy.
zithromax-sr 2g, special investigation (regulatory post marketing commitment plan)

Conditions: Bacterial Infections

Summary: to collect the efficacy and safety information of zithromax-sr related to their appropriate use in daily practice.

all the patients whom an investigator prescribes the first azithromycin sr should be registered within 14 days.

Eligibility criteria:
inclusion criteria: * male or female subjects diagnosed with skin and soft tissue infection, sexually-transmitted infection, and infection of the oral. * subjects must have no prior experience with azithromycin sr. exclusion criteria: * patients not administered azithromycin sr.

Keywords: skin infection soft tissue infection sexually-transmitted infection infection oral regulatory post marketing commitment plan
stanford rad-at study (research on anxiety and depression - anhedonia treatment)

Conditions: Anxiety; Depression

Summary: this research study is aimed at understanding behaviors and brain circuits that relate to anxiety and depression. our goal is to learn which circuits of the brain are involved in anxiety and how these circuits might affect daily functioning. this study has recently added an additional treatment component: participants undergo a 12 week course of either pramipexole medication or rtms therapy (explained below). the ultimate goal of the study is to offer participants experiencing anxiety and depression a treatment that is alternative to ones that have failed them in the past, and to apply the knowledge we gain from investigating the brain circuits involved in anxiety and depression to help personalize treatments. we invite anyone who has recently experienced any symptoms of anxiety and/or depression to participate (no diagnosis is required to participate).

if you are eligible and choose to participate, we'll ask you to come in for 2 separate testing visits and 8 weeks of treatment in between. in both the pre-treatment and post-treatment testing visit, you would complete game-like tasks on the computer, undergo a non-invasive mri brain scan, and answer some questions about your emotional health. the entire visit takes place during 1-2 days at stanford and lasts about 4-5 hours. we'll also ask you to complete a follow-up 12 weeks later, from home, during which we'll again ask you some questions on your emotional health. the 8-week treatment phase will consist of your choice of either tms (transcranial magnetic stimulation) or pramipexole (a medication for depression). you will meet with study coordinators and mds each week (pramipexole) or each day (tms) to receive treatment. you will also be asked to complete weekly online surveys to monitor your mood during the 2-month course of treatment. to inquire more about participation, you can either sign up online or contact us. sign up online: http://med.stanford.edu/williamslab/research/current/rad.html contact us: call or text (650) 600-1609 or email rad-at-study@stanford.edu

Eligibility criteria:
inclusion criteria: * recent experiences of anxiety and/or depression * ages 18-65 exclusion criteria: * specific psychiatric medications (case-by-case basis) * a diagnosis of bipolar 1 disorder, schizophrenia, or obsessive compulsive disorder * any of the following medical conditions: parkinson's disease; liver or kidney disease; history of epilepsy or seizures; history of cardiovascular disorders (specifically orthostatic hypotension)

Keywords: anxiety depression social anxiety disorder bipolar disorder ii ptsd gad phobia
phase ii study to investigate the kinetics of the immune response generated by influenza virus vaccine.

Conditions: Influenza

Summary: the primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types a \& b, live, cold-adapted (liquid formulation caiv-t; wyeth, marietta, pa).

this was a randomized, open-label, placebo-controlled, outpatient study carried out in healthy adults 18 to \< 65 years of age. the study was designed to evaluate the kinetics of the immune responses generated by each of the study products in order to determine the best sampling time for future studies. subjects were randomized in a 1:1:1 ratio to receive a single dose of either caiv-t, inactivated influenza virus vaccine (tiv), or placebo.

Eligibility criteria:
inclusion criteria: * subjects had to have been at least 18 years of age and less than 65 years of age at the time informed consent was obtained; * women of child-bearing potential had to use reliable methods of hormonal and/or nonhormonal contraception (which includes cervical cap, diaphragm, condoms with spermicide or iud) during sexual intercourse throughout the entire study period; a negative urine pregnancy test (with detection limit of less than or equal to 25miu/ml) no more than 24 hours prior to vaccine administration; and agreed to avoid pregnancy during participation in the study. a urine pregnancy test was also conducted at the completion of study participation. females who were surgically sterile at time of enrollment were not required to undergo pregnancy testing. * who were determined by medical history, physical examination and clinical judgement to be eligible for the study. * who provided written informed consent after the nature of the study has been explained; * who were available for one month duration of the trial (from enrollment to study completion); * who could be reached by study staff for the post-vaccination contact \[telephone, clinic or home visit\]. exclusion criteria: * who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period; * with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids and intranasal steroids; or cytotoxic agents; * who had an immunosuppressed or an immunocompromised individual living in the same household; * who had a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo; * who received any commercially-available or investigational injected influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment; * who previously received an intranasally administered influenza vaccine; * who had any medical conditions that, in the opinion of the investigator, might interfere with interpretation of the study results;